T-cell receptor therapy shows early anti-tumor activity in phase I study

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Elbert Y. Kuo, a thoracic surgeon who specializes in minimally invasive techniques, has joined Baptist MD Anderson Cancer Center as head of the Division of Surgery and surgeon-in-chief.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.

July 18, 2025

Vol.51 No.28

Clinical Trials & Tribulations

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

The windows down the hall from the operating room scrub sinks at MD Anderson Cancer Center look out at the tower of Texas Children’s Hospital.

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT Southwestern published in Nature.

June 13, 2025

Vol.51 No.23

T-cell receptor therapy shows early anti-tumor activity in phase I study

YOU MAY BE INTERESTED IN

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

An overlooked immune cell population may offer new direction for cell and gene therapy

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Renew today!

Subscriber content

Never miss an issue!

Login